Uyar, GC, Mirallas, O, Baskurt, K, Martin-Cullell, B, Yesilbas, E, Recuero-Borau, J, Kaya, S, Garcés, VN, Yücel, SE, Cano, KSV, Gómez-Puerto, D, Gómez, AP, de Torres, CS, Öksüzoglu, ÖBÇ, Serradell, S, Dienstmann, R, Sutcuoglu, O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Regional Health-Europe. 2025; 54DOI:10.1016/j.lanepe.2025.101317. PMID:40672056. IF:13.000(Q1/1D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC (vol 6, 100815, 2025). Jto Clinical And Research Reports. 2025; 6(7)DOI:10.1016/j.jtocrr.2025.100842. PMID:40534993. IF:(Q/D).

Pietrantonio, F, Salvatore, L, Esaki, T, Modest, DP, Lopez-Bravo, DP, Taieb, J, Karamouzis, MV, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Chan, EMY, Chao, JS, Tran, Q, Cremolini, C, Fakih, M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(19)DOI:10.1200/JCO-24-02026. PMID:40215429. IF:41.900(Q1/1D).

Bergmann, L, Albiges, L, Ahrens, M, Gross-Goupil, M, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suarez, C, Maroto, P, Grünwald, V, Oosting, SF, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Haanen, JB. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. ANNALS OF ONCOLOGY. 2025; 36(7)DOI:10.1016/j.annonc.2025.03.016. PMID:40180121. IF:65.400(Q1/1D).

Da Silva, IM, Riera, P, Bernal, S, Manrique, ACV, Cullell, BM, Paez, D. Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.046. PMID:. IF:65.400(Q1/1D).

Beltran, JS, Serda, PC, Cardozo, AR, Pérez, MAM, Manrique, ACV, Paez, D, Cullell, BM. A retrospective single-center analysis of treatment strategies and real-world outcomes in locally advanced pancreatic cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.288. PMID:. IF:65.400(Q1/1D).

Ponce, CG, Méndez, AM, Plazas, JG, Benavente, MDL, Serda, PC, Vazquez, EB, Conesa, MADLAV, Gil, RHS, Gomez, VL, Alfonso, AL, Custodio-Cabello, S, Paladines, WGP, Carmena, MD, Mercade, TM, Tabares, MLS, Martínez, IP, Gutierrez, LC, Martin, AJM, Fonseca, PJ, Pacheco-Barcia, VE. Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: Results from the PANTHEIA-SEOM study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.304. PMID:. IF:65.400(Q1/1D).

Pacheco-Barcia, VE, Méndez, AM, Plazas, JG, Rus, ND, Benavente, MDL, Cullell, BM, Gomez, VL, Vazquez, EB, Conesa, MADLAV, Fernandez, SP, Alfonso, AL, Castet, F, Adeva, JA, Fabregat, C, Abad, DG, Contreras, PZ, Carmona-Bayonas, A, Fonseca, PJ, Gutierrez, LC, Martin, AJM. Impact of the systemic inflammation index (SIRI) and artificial intelligence(AI)-based muscle mass (FocusedON® software) on chemotherapy toxicity and prognosis in metastatic pancreatic cancer: A proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.05.305. PMID:. IF:65.400(Q1/1D).